Skip to main content
This site is intended only for US healthcare professionals.
To decrease the incidence of chemotherapy-induced myelosuppression in adult patients when
administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen

For extensive-stage small cell lung cancer (ES-SCLC)

PROTECT
   THEM ALL

COSELA is the first and only proactive therapy that helps prevent chemotherapy-induced myelosuppression by protecting hematopoietic stem and progenitor cells1,2
In the clinical trials, only neutrophils, erythrocytes, and platelets were studied. Hematopoietic stem and progenitor cells, however, are the source of all blood lineages. Additional data is needed to evaluate efficacy beyond what is included in the presented studies.

Trilaciclib is a recommended option in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and ASCO® clinical guidelines.3-5 LEARN MORE

To decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen

For extensive-stage small cell lung cancer (ES-SCLC)

PROTECT
THEM ALL

COSELA is the first and only proactive therapy that helps prevent chemotherapy-induced myelosuppression by protecting hematopoietic stem and progenitor cells1,2

In the clinical trials, only neutrophils, erythrocytes, and platelets were studied. Hematopoietic stem and progenitor cells, however, are the source of all blood lineages. Additional data is needed to evaluate efficacy beyond what is included in the presented studies.
In the clinical trials, only neutrophils, erythrocytes, and platelets were studied. Hematopoietic stem and progenitor cells, however, are the source of all blood lineages. Additional data is needed to evaluate efficacy beyond what is included in the presented studies.
Trilaciclib is a recommended option in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and ASCO® clinical guidelines.3-5 LEARN MORE